An interventional study of Audit and feedback through a quality registry and Implementation support in Myocardial Infarction and Risk Reduction, sponsored by Skane University Hospital. Enrolling by invitation at 1 site in Sweden. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-11-29.
Sponsored by Skane University Hospital · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in Myocardial Infarction with a site in Sweden — 13 open to participants now, 22 under way, 4 of them phase 3. Myocardial Infarction · Sweden.
Among the 90 studies in Myocardial Infarction with a site in Sweden, this one is the 60th largest by planned enrollment of the 70 interventional ones that give a count, is one of 4 that started in 2023, is one of 23 with no phase, reaches primary completion later than 9 of the 21 other live ones, and was the 77th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →13 of the 90 studies in Myocardial Infarction with a site in Sweden are open now. Recruiting first, the newest first:
Uppsala University · Sites in Sweden
Ages 18–55
Abcentra · Sites in Sweden, United States, Czechia and 6 more countries
Ages 18+
Karolinska Institutet · Sites in Sweden
Ages 18+ · Healthy volunteers
Karolinska Institutet · Sites in Sweden
Ages 18+
Uppsala University · Sites in Sweden
Ages 50–80
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 11 · Phase 3 26 · Phase 4 11
First in 1997; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is below the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 875 across the 70 interventional studies, 5,518 across the 20 observational. Of the 64 that completed or were terminated, 21 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 90 have an industry lead sponsor. The 10 most frequent:
Skane University Hospital is the lead sponsor of 73 studies on the registry; 17 are open to participants now.
Skane University Hospital has 2 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
6 of the studies in Myocardial Infarction with a site in Sweden that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT05889416Skane University HospitalThe Perfect-CR Implementation Study | 2026-12 |
| NCT03620266Ole Frobert, MD, PhDEffects of Bilberry and Oat Intake After Type 2 Diabetes and/or MI | 2026-12-31 |
| NCT07706816Uppsala UniversityEvaluation of a Remote Behavioural Stress Recovery Intervention for Myocardial Infarction Patients Younger Than Fifty-five (BRIM-55): A Feasibility Study | 2027-01-31 |
| NCT06927739AbcentraFocused Orticumab Research for Treating Inflammation in Coronary Arteries | 2027-02-08 |
Add all 6 to your calendar (.ics) → With an account.
Among the 90 studies in Myocardial Infarction with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this open-label cluster-randomized effectiveness-implementation hybrid trial is to study whether a) audit and feedback of cardiac rehabilitation service delivery within a national quality registry and b) structured implementation support can improve center-level adherence to guidelines and short and long-term patient-level outcomes.
Administering secondary prevention via structured cardiac rehabilitation (CR) programs for patients who have suffered a myocardial infarction (MI) reduces mortality and morbidity and improves quality of life. Still, treatment goal achievement at patient-level and service delivery at center-level are sub-optimal and there is a large variation in program structure and delivery at center-level.
Using an open-label cluster-randomized effectiveness-implementation hybrid trial design, the primary objective of this study is to prospectively evaluate whether a) audit and feedback of CR processes and structures within the national cardiac registry SWEDEHEART and b) supporting CR centers in implementing CR guidelines can increase center-level guideline adherence. The secondary objectives are the following:
All CR centers in Sweden (approximately 75 centers) will be offered participation in the study. Collectively these centers attend to approximately 8000 patients/year. Patient-level outcome data will be retrieved from national registries.
Centre-level
Inclusion Criteria:
Exclusion Criteria:
Patient-level
Inclusion Criteria:
Exclusion Criteria:
Implementation of national guidelines on secondary prevention according to local plan and preferences
Audit and feedback on implementation of national guidelines on secondary prevention through the national quality registry SWEDEHEART
Other: Audit and feedback through a quality registry
Audit and feedback through the national quality registry SWEDEHEART and structured implementation support for implementation of national guidelines on secondary prevention
Other: Audit and feedback through a quality registry · Other: Implementation support
Centres answer CR process and structure variables through the SWEDEHEART registry every six months for three years. Feedback will be accessible online and through annual reports, enabling comparisons with own prior and other centres´ results.
On-site support to implement guidelines on secondary prevention applying practice facilitation - a multifaceted approach carried out by CR experts who enable personnel at intervention centres to address and overcome challenges in implementing guidelines.
Adherence score
The adherence score reflects center-level adherence to CR processes and structures as recommended in national guidelines on secondary prevention. The score is derived from 39 variables capturing guideline-directed CR structure and processes collected on center-level through the national cardiac registry SWEDEHEART. The score ranges from 0 (worst) to 39 (best).
Time frame: 3 years
Blood pressure target attainment
For patients \<70 years of age \<130/80 mmHg and for patients ≥70 years \<140/80 mmHg (yes/no)
Time frame: One year
Systolic blood pressure
Continuous variable in mmHg
Time frame: One year
Low-density lipoprotein cholesterol target attainment
\<1.4 mmol/L (yes/no)
Time frame: One year
Low-density lipoprotein cholesterol
Continuous variable in mmol/L
Time frame: One year
Self-reported quality of life
Measured using EuroQoL-Visual Analogue Scale (EQ-VAS) - a vertical visual analogue scale with a range of values between 100 (best imaginable health) and 0 (worst imaginable health)
Time frame: One year
Self-reported smoking status
Never smoker, former smoker (\>1 month) or current smoker
Time frame: One year
Self-reported dietary habits
Dietary habits are assessed by self-report through four questions covering intake of fruit, vegetables, fish and sweets. Each question gives points ranging from 0 (worst) to 3 (best), summing up to a total score of 0-12 points.
Time frame: One year
Self-reported physical activity
Number of days during the last week the patient has been physically active for a minimum of 30 minutes (at least 10 minutes at a time) with activity causing shortness of breath and a slightly increased pulse, corresponding to a brisk walk. Permissible values can thus range from 0 days (worst) to 7 days (best).
Time frame: One year
Attendance in an exercise-based CR programme
Attended for at least 3 months (yes/no)
Time frame: One year
Major adverse cardiovascular events (MACE)
A composite endpoint of the following events: * cardiovascular mortality * non-fatal MI * non-fatal ischemic stroke * coronary revascularization * hospitalization for new or worsening heart failure
Time frame: Five years
Total mortality
Death from any cause.
Time frame: Five years
Acceptability of the implementation support
Acceptability reflects the degree to which the intervention is perceived as being feasible, desirable, and appropriate by stakeholders (healthcare providers, i.e., the CR team and organizational leaders) and the level of preparedness of the organization to adopt the intervention. Acceptability will be assessed through semi-structured interviews with healthcare personnel at centers subject to the implementation intervention. Interview guides, allowing for flexibility in terms of order and form of questions and topics, using mainly open-ended and neutral questions will be developed. The exact number of interviews will be decided on after start of the study and will continue until a) no new concepts or categories are identified and b) when there is no need for further elaboration of these.
Time frame: Assessed at the time of implementation
Adoption of the implementation support
Adoption determines the extent to which the intervention is used in practice. Adoption of the implementation support will be assessed through semi-structured interviews with healthcare personnel at centers subject to the implementation intervention.
Time frame: Assessed six months after the implementation support has been provided
Fidelity of the implementation support
Fidelity reflects the degree to which the implementation used in practice adheres to the original design of the intervention. Fidelity will be assessed through semi-structured interviews with healthcare personnel at centers subject to the implementation intervention.
Time frame: Assessed six months after the implementation support has been provided
Implementation cost and cost effectiveness
Reflects resources required to implement the intervention, including the cost of material, staff, and any other expenses incurred as a result of the implementation of the intervention. Based on the cost estimates and the effect of the implementation assistance on patient outcomes, the economic evaluation will then be able to calculate cost-effectiveness ratios.
Time frame: Assessed at the time of implementation
Plan to share: No — The data to be used in this study is based on the SWEDEHEART registry. Access to data from the registry needs to be applied for and third-party data usage is not allowed, irrespective of whether the data contain potentially identifying or sensitive data or not. Instead, given ethical study approval from the Swedish Ethical Review Authority, access to SWEDEHEART data can be applied for from the Uppsala Clinical Research Center (UCR) in Sweden. Further information can be found on the UCR www.ucr.uu.se/en/ and Swedish Ethical Review Authority etikprovningsmyndigheten.se/ websites.
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Dec 2026, 38 months after the start.
Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 38 months is close to that.
Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Skane University Hospital